Article
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indicat
Rating:
0.0
Views:
46
Likes:
1
Library:
1
AstraZeneca's flagship cancer drug is adding a new indication to its fleet. Friday afternoon, the FDA granted Tagrisso the thumbs-up in non-small cell lung cancer for patients with EGFR mutations who had undergone tumor resection and optional, standard postoperative adjuvant chemotherapy. It's another win for the drug as a prominent
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value